Medium-molecular weight hyaluronic acid orchestrates hair follicle regeneration via CD44/AKT-driven endogenous ROS activation of β-catenin.

Hyaluronic acid-based control/target delivery system: Formation, control release and applications.

Hyaluronic acid-based strategies for prostate cancer therapy.

Box-Behnken design-based development and optimization of potentiated antibacterial nanoemulgel for azithromycin

A Study to Evaluate Efficacy and Safety of Hydeal Cyst Intravesical Instillations in Non-muscle Invasive Bladder Cancer Patients Treated With Intravesical Chemotherapy or Immunotherapy.

Design of albumin-based nanotherapeutics for glioblastoma management: Biological barriers, targeting strategies, and translational perspectives.

Intra-articular therapies for synovial joint dysfunction: a comprehensive integrative review.

Electrospun PVA-PCL/HA nanofiber scaffolds containing mupirocin for surgical wound healing in Sprague Dawley rats.

ROS-amplifying HKUST-1 nanozyme for enhanced colon cancer therapy.

Design and synthesis of fluorescent calix[4]arene-1,8-Naphthalimide derivatives: Transparent biofilms, antioxidant and antimicrobial properties, and real-samples applications.

Oral lichen planus (OLP) is a chronic inflammatory disorder with limited topical treatment options and long-term corticosteroid dependency. This study investigates a novel atorvastatin-loaded hyalurosomal gel (ATV-Hyalugel) as a topical adjuvant to reduce systemic corticosteroid use in severe OLP. The objective of the study isto develop, optimize, characterize ATV-Hyalugel and evaluate its clinical efficacy in a randomized controlled clinicaltrial. ATV-loaded hyalurosomes (ATV-HAs) were prepared via thin-film hydration and optimized using an I-optimal mixture design (independent variables: phospholipid, Tween 80, and hyaluronic acid; responses: entrapment efficiency (EE%), particle size (PS), and zeta potential (ZP). The optimal formulation was incorporated into a chitosan gel, which was characterized for its pH, rheological behavior, and in-vitro drug release. Four weeks randomized controlled trial (n = 90) compared: group one received standard prednisolone (40 mg/day) while group two received half-dose prednisolone (20 mg/day) in combination with ATV-Hyalugel (topically, three times daily). Pain and ulcer scores were recorded weekly. Between-group comparisons were performed using the Mann-Whitney U test (non-parametric; α = 0.05), and within-group improvement from baseline to Week 4 was assessed using the Kruskal-Wallis test. Optimized ATV-HAs demonstrated high EE%(79.1 ± 0.4%), uniform PS(221.2 ± 5.1 nm), and stable ZP(-31.6 ± 0.2 mV). ATV-Hyalugel exhibited mucosa-compatible pH (6.48 ± 0.2), pseudoplastic rheology, and a sustained release profile dominated by diffusion-driven kinetics. Clinically, group two achieved therapeutic equivalence to group one by Week 2 (p > 0.05), despite receiving 50% less corticosteroid. Both groups showed significant symptom reduction from baseline to Week four (p < 0.0001, Kruskal-Wallis). No adverse events were reported with ATV-Hyalugel. ATV-Hyalugel enables a 50% corticosteroid dose reduction while maintaining clinical efficacy. Its favorable release kinetics and safety profile support its use as an innovative adjuvant therapy for severe OLP.

Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption.

Cascade-responsive hydrogen sulfide-releasing nanoplatform for synergistic tumor photothermal-immunotherapy.

In situ electrocrosslinkable and immiscible bioadhesive for robust underwater electrophysiological signal interfaces.

Novel bowl-shaped Fe3O4 magnetic nanoparticles with hyaluronic acid coating for superior drug delivery

Dynamic chitosan-hyaluronic acid hydrogels for extrusion printing: Combined effects of polymer molecular weight and carbon nanofillers.

Injectable thermoresponsive carboxymethyl chitosan–hyaluronic acid hydrogel reinforced with mesoporous silica nanoparticles for efficient cationic drug delivery

Acne is a multifactorial dermatological condition driven by Propionibacterium acnes (P. acnes) infection, inflammation, and sebum dysregulation. While essential oils, such as Angelica sinensis (Danggui) essential oil (AEO), exhibit antimicrobial and anti-inflammatory properties, their clinical application is hindered by poor solubility, stability, and skin penetration. To address these limitations, we developed hydroxypropyl-β-cyclodextrin (HPCD)-complexed AEO-loaded microneedles (AEO@HPCD MNs) using hyaluronic acid for enhanced transdermal delivery. The optimized AEO@HPCD MNs demonstrated superior mechanical strength, rapid dissolution, and efficient cargo release. In vitro studies confirmed potent antibacterial activity against P. acnes, while in vivo experiments revealed significant reductions in acne lesion size and IL-1β levels. RNA sequencing of treated acne lesions identified key downregulated genes (Fpr1, Rarres2, Cxcl5, Gbp3, Hck, Gbp7, Librb4a, Psmb8) and enriched pathways, including innate immunity and inflammatory responses. Notably, AEO@HPCD MNs suppressed 5α-reductase and fatty acid synthase (FAS) expression, demonstrating-for the first time-AEO's ability to normalize sebum production. Mechanistically, AEO@HPCD MNs exert multifaceted therapeutic effects: (1) direct antibacterial activity against P. acnes, (2) suppression of inflammatory and immune-related pathways through modulation of Toll-like receptor, NOD-like receptor, and cytokine-cytokine receptor signaling pathways, (3) regulation of sebum production via lipid-metabolic gene expression modulation, and (4) enhanced delivery efficiency and microenvironment modification through the physical action of microneedles, collectively contributing to synergistic acne therapy. This study develops a microneedle delivery platform that addresses both essential oil instability and inclusion complex delivery challenges while targeting multiple acne pathogenic factors. The AEO@HPCD MNs provide a safe, minimally invasive, multifunctional therapeutic strategy for acne treatment.

Molecular weight of hyaluronic acid critically determines the structural and functional properties of its conjugates with milk proteins

Osteoarthritis affects millions worldwide, yet current intra-articular treatments provide limited durability due to rapid therapeutics clearance and poor intrinsic cartilage repair capacity. We present an injectable, pore-forming hydrogel platform designed for controlled delivery of platelet-derived bioactive factors while promoting cell infiltration for cartilage regeneration. The system integrates functionalized gelatin and hyaluronic acid networks with oxidized alginate microparticles that act simultaneously as porogens and platelet lysate (PL) carriers, generating a dynamic microenvironment favorable for tissue repair. Microparticles produced via emulsification/internal gelation show tunable degradation governed by alginate oxidation, enabling programmable release kinetics. Hydrogels containing 10% (w/v) microparticles exhibited a compressive modulus of 37.7kPa and photocrosslinked in under 60s, supporting minimally invasive arthroscopic use. Release studies confirmed sustained protein delivery for up to 31days, with oxidized microparticles (5% oxidation) releasing over 95% of encapsulated PL in correlation with their degradation, while blending with unmodified alginate offered further tunability. In chondrocyte-loaded constructs, PL-releasing hydrogels significantly enhanced proliferation and extracellular matrix deposition. Immunofluorescence showed increased aggrecan and collagen type-II, indicating preservation of chondrocyte phenotype and hyaline-like matrix formation. This dual-function injectable system couples localized trophic factor release with porosity-driven cell migration, offering a promising polysaccharide-centred strategy for clinically translatable cartilage repair.